(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.
The three biggest winners today are Kodak, Okta, and Celsius Holdings.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Kodak (KODK) | 5.33 | 52.28% | 2024-02-29 15:56:12 |
| 2 | Okta (OKTA) | 107.10 | 22.68% | 2024-02-29 15:16:50 |
| 3 | Celsius Holdings (CELH) | 81.93 | 20.89% | 2024-02-29 15:15:58 |
| 4 | Beyond Meat (BYND) | 11.48 | 16.78% | 2024-02-29 15:15:54 |
| 5 | Upland Software (UPLD) | 3.02 | 14.2% | 2024-02-29 15:15:13 |
| 6 | Hormel Foods (HRL) | 34.88 | 13.12% | 2024-02-29 15:20:35 |
| 7 | Novavax (NVAX) | 4.99 | 13.04% | 2024-02-29 15:14:01 |
| 8 | LendingTree (TREE) | 39.40 | 11.41% | 2024-02-29 15:14:58 |
| 9 | Catalyst Pharmaceuticals (CPRX) | 15.96 | 9.62% | 2024-02-29 15:11:28 |
| 10 | AMD (AMD) | 190.70 | 8.02% | 2024-02-29 15:10:33 |
The three biggest losers today are Castle Biosciences, Canaan, and Marathon.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Castle Biosciences (CSTL) | 17.97 | -26.32% | 2024-02-29 15:16:04 |
| 2 | Canaan (CAN) | 1.56 | -15.67% | 2024-02-29 14:15:44 |
| 3 | Marathon (MARA) | 26.17 | -15.65% | 2024-02-29 15:13:32 |
| 4 | Viking Therapeutics (VKTX) | 80.07 | -15.27% | 2024-02-29 15:17:39 |
| 5 | AMC (AMC) | 4.33 | -13.23% | 2024-02-29 15:18:14 |
| 6 | Riot Blockchain (RIOT) | 13.99 | -10.61% | 2024-02-29 15:17:04 |
| 7 | FibroGen (FGEN) | 1.80 | -9.57% | 2024-02-29 15:12:14 |
| 8 | Cronos Group (CRON) | 2.05 | -9.29% | 2024-02-29 14:15:50 |
| 9 | Xcel Energy (XEL) | 52.76 | -8.51% | 2024-02-29 15:17:44 |
| 10 | Ambev (ABEV) | 2.52 | -6.32% | 2024-02-29 15:52:07 |
Winners today
1. Kodak (KODK) – 52.28%
Eastman Kodak Company provides hardware, software, consumables, and services to customers in the commercial print, packaging, publishing, manufacturing, and entertainment markets worldwide. The company operates through four segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment offers digital offset plate and computer-to-plate imaging solutions to commercial industries, including commercial print, direct mail, book publishing, newspapers and magazines, and packaging. The Digital Printing segment provides electrophotographic printing solutions, such as The ASCEND and NEXFINITY printers; prosper products, including the PROSPER 6000 Press, PROSPER Writing Systems, PROSPER press systems, and PROSPER components; versamark products; and PRINERGY workflow production software. The Advanced Materials and Chemicals segment engages in industrial film and chemicals, motion picture, and advanced materials and functional printing businesses. This segment also comprises the Kodak Research Laboratories, which conducts research, develops new product or new business opportunities, and files patent applications for its inventions and innovations, as well as manages licensing of its intellectual property to third parties. The Brand segment engages in the licensing of Kodak brand to third parties. The company engages in the operation of Eastman Business Park, a technology center and industrial complex. It sells its products and services through direct sales, third party resellers, dealers, channel partners, and distributors. Eastman Kodak Company was founded in 1880 and is headquartered in Rochester, New York.
NYSE ended the session with Kodak rising 52.28% to $5.33 on Thursday, following the last session’s downward trend. NYSE jumped 0.23% to $17,613.45, following the last session’s downward trend on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, Kodak has a trailing twelve months EPS of $0.69.
PE Ratio
Kodak has a trailing twelve months price to earnings ratio of 7.72. Meaning, the purchaser of the share is investing $7.72 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.79%.
More news about Kodak.
2. Okta (OKTA) – 22.68%
Okta, Inc. provides identity solutions for enterprises, small and medium-sized businesses, universities, non-profits, and government agencies in the United States and internationally. The company offers Okta's, a suite of products and services is used to manage and secure identities, such as Universal Directory, a cloud-based system of record to store and secure user, application, and device profiles for an organization; Single Sign-On that enables users to access applications in the cloud or on-premise from various devices; Adaptive Multi-Factor Authentication provides a layer of security for cloud, mobile, Web applications, and data; Lifecycle Management that enables IT organizations or developers to manage a user's identity throughout its lifecycle; API Access Management that enables organizations to secure APIs; Access Gateway enables organizations to extend the Workforce Identity Cloud; Advanced Server Access to manage and secure cloud infrastructure; and Okta Identity Governance, an identity access management and identity governance solutions. It also provides Universal Login allows customers to provide login experience across different applications and devices; Attack Protection, a suite of security capabilities that protect from malicious traffics; Adaptive Multi-Factor Authentication that minimizes friction to end users; Passwordless authentication enables users to login without a password and supports in various login methods; Machine to Machine provides standards-based authentication and authorization; Private Cloud that allows customers to run a dedicated cloud instance of Customer Identity Cloud; In addition, the company provides organization; Actions and Extensibility; and Enterprise Connections. It sells its products directly to customers through sales force and channel partners. The company was formerly known as Saasure, Inc. Okta, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
NASDAQ ended the session with Okta jumping 22.68% to $107.10 on Thursday, after five successive sessions in a row of gains. NASDAQ rose 0.9% to $16,091.92, following the last session’s downward trend on what was a somewhat up trend trading session today.
Earnings Per Share
As for profitability, Okta has a trailing twelve months EPS of $-2.86.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -8.33%.
Volatility
Okta’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.84%, a negative 0.07%, and a positive 2.12%.
Okta’s highest amplitude of average volatility was 1.84% (last week), 2.39% (last month), and 2.12% (last quarter).
Volume
Today’s last reported volume for Okta is 18278600 which is 714.35% above its average volume of 2244550.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 70% and 90.9%, respectively.
Previous days news about Okta
- Okta (okta) beats Q4 earnings and revenue estimates. According to Zacks on Wednesday, 28 February, "While Okta has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
- Okta (okta) Q4 earnings: taking a look at key metrics versus estimates. According to Zacks on Wednesday, 28 February, "For the quarter ended January 2024, Okta (OKTA Quick QuoteOKTA – Free Report) reported revenue of $605 million, up 18.6% over the same period last year. ", "Here is how Okta performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"
More news about Okta.
3. Celsius Holdings (CELH) – 20.89%
Celsius Holdings, Inc. develops, processes, markets, distributes, and sells functional drinks and liquid supplements in the United States and internationally. The company offers various carbonated and non-carbonated functional energy drinks under the CELSIUS Originals name; dietary supplement in carbonated flavors, including apple jack'd, orangesicle, inferno punch, cherry lime, blueberry pomegranate, strawberry dragon fruit, tangerine grapefruit, and jackfruit under the CELSIUS HEAT name; and branched-chain amino acids functional energy drink that fuels muscle recovery under the CELSIUS BCCA+ENERGY name. It also provides CELSIUS On-the-Go, a powdered form of the active ingredients in functional energy drinks in individual On-The-Go packets and canisters; and sparkling grapefruit, cucumber lime, and orange pomegranate, as well as pineapple coconut, watermelon berry, and strawberries and cream non-carbonated functional energy drinks under the CELSIUS Sweetened name; and CELSIUS ready-to drink products. It distributes its products through direct-to-store delivery distributors and direct to retailers, include supermarkets, convenience stores, drug stores, nutritional stores, and mass merchants, as well as health clubs, spas, gyms, the military, and e-commerce websites. The company was formerly known as Vector Ventures, Inc. and changed its name to Celsius Holdings, Inc. in January 2007. Celsius Holdings, Inc. was founded in 2004 and is headquartered in Boca Raton, Florida.
NASDAQ ended the session with Celsius Holdings jumping 20.89% to $81.93 on Thursday, after three successive sessions in a row of gains. NASDAQ jumped 0.9% to $16,091.92, following the last session’s downward trend on what was a somewhat up trend exchanging session today.
Celsius holdings inc. (celh) surpasses Q4 earnings and revenue estimatesWhile Celsius Holdings Inc. Has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?, Ahead of this earnings release, the estimate revisions trend for Celsius Holdings Inc. Mixed.
Celsius holdings inc. (celh) reports Q4 earnings: what key metrics have to sayFor the quarter ended December 2023, Celsius Holdings Inc. (CELH Quick QuoteCELH – Free Report) reported revenue of $347.44 million, up 95.2% over the same period last year. , Here is how Celsius Holdings Inc. performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Earnings Per Share
As for profitability, Celsius Holdings has a trailing twelve months EPS of $0.48.
PE Ratio
Celsius Holdings has a trailing twelve months price to earnings ratio of 170.69. Meaning, the purchaser of the share is investing $170.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.18%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 225% and 46.2%, respectively.
Moving Average
Celsius Holdings’s worth is way higher than its 50-day moving average of $55.87 and way above its 200-day moving average of $53.61.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Celsius Holdings’s stock is considered to be oversold (<=20).
Sales Growth
Celsius Holdings’s sales growth is 85.4% for the ongoing quarter and 77.6% for the next.
More news about Celsius Holdings.
4. Beyond Meat (BYND) – 16.78%
Beyond Meat, Inc. develops, manufactures, markets, and sells plant-based meat products in the United States and internationally. The company sells a range of plant-based meat products across the platforms of beef, pork, and poultry. It sells its products through grocery, mass merchandiser, club, convenience, and natural retailer channels, as well as various food-away-from-home channels, including restaurants, foodservice outlets, and schools. The company was formerly known as Savage River, Inc. and changed its name to Beyond Meat, Inc. in September 2018. Beyond Meat, Inc. was founded in 2009 and is headquartered in El Segundo, California.
NASDAQ ended the session with Beyond Meat rising 16.78% to $11.48 on Thursday, after two consecutive sessions in a row of gains. NASDAQ rose 0.9% to $16,091.92, following the last session’s downward trend on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, Beyond Meat has a trailing twelve months EPS of $-5.26.
More news about Beyond Meat.
5. Upland Software (UPLD) – 14.2%
Upland Software, Inc. provides cloud-based enterprise work management software in the United States, the United Kingdom, Canada, and internationally. It offers a family of software applications under the Upland brand in the areas of marketing, sales, contact center, project management, information technology, business operations, and human resources and legal. The company also provides professional services, such as implementation, data extraction, integration and configuration, and training services, as well as customer support services. It serves large global corporations, various government agencies, and small and medium-sized businesses, as well as financial, consulting, technology, manufacturing, media, telecommunication, political, healthcare, life sciences, and retail and hospitality sectors. The company was formerly known as Silverback Enterprise Group, Inc. and changed its name to Upland Software, Inc. in November 2013. Upland Software, Inc. was incorporated in 2010 and is headquartered in Austin, Texas.
NASDAQ ended the session with Upland Software jumping 14.2% to $3.02 on Thursday while NASDAQ rose 0.9% to $16,091.92.
Earnings Per Share
As for profitability, Upland Software has a trailing twelve months EPS of $-5.77.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -54.09%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Upland Software’s EBITDA is 51.81.
More news about Upland Software.
6. Hormel Foods (HRL) – 13.12%
Hormel Foods Corporation develops, processes, and distributes various meat, nuts, and other food products to retail, foodservice, deli, and commercial customers in the United States and internationally. It operates through three segments: Retail, Foodservice, and International segments. The company provides various perishable products that include fresh meats, frozen items, refrigerated meal solutions, sausages, hams, guacamoles, and bacons; and shelf-stable products comprising canned luncheon meats, nut butters, snack nuts, chili, shelf-stable microwaveable meals, hash, stews, tortillas, salsas, tortilla chips, nutritional food supplements, and others. It sells its products under the HORMEL, ALWAYS TENDER, APPLEGATE, AUSTIN BLUES, BACON 1, BLACK LABEL, BREAD READY, BURKE, CAFÉ H, CERATTI, CHI-CHI'S, COLUMBUS, COMPLEATS, CORN NUTS, CURE 81, DAN'S PRIZE, DI LUSSO, DINTY MOORE, DON MIGUEL, DOÑA MARIA, EMBASA, FAST ‘N EASY, FIRE BRAISED, FONTANINI, HAPPY LITTLE PLANTS, HERDEZ, HORMEL GATHERINGS, HORMEL SQUARE TABLE, HORMEL VITAL CUISINE, HOUSE OF TSANG, JENNIE-O, JUSTIN'S, LA VICTORIA, LAYOUT, LLOYD'S, MARY KITCHEN, MR. PEANUT, NATURAL CHOICE, NUT-RITION, OLD SMOKEHOUSE, OVEN READY, PILLOW PACK, PLANTERS, ROSA GRANDE, SADLER'S SMOKEHOUSE, SKIPPY, SPAM, SPECIAL RECIPE, THICK & EASY, VALLEY FRESH, AND WHOLLY brands through sales personnel, independent brokers, and distributors. The company was formerly known as Geo. A. Hormel & Company and changed its name to Hormel Foods Corporation in January 1995. Hormel Foods Corporation was founded in 1891 and is headquartered in Austin, Minnesota.
NYSE ended the session with Hormel Foods rising 13.12% to $34.88 on Thursday, after two sequential sessions in a row of losses. NYSE jumped 0.23% to $17,613.45, following the last session’s downward trend on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, Hormel Foods has a trailing twelve months EPS of $1.45.
PE Ratio
Hormel Foods has a trailing twelve months price to earnings ratio of 24.05. Meaning, the purchaser of the share is investing $24.05 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.38%.
More news about Hormel Foods.
7. Novavax (NVAX) – 13.04%
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
NASDAQ ended the session with Novavax rising 13.04% to $4.99 on Thursday while NASDAQ jumped 0.9% to $16,091.92.
Earnings Per Share
As for profitability, Novavax has a trailing twelve months EPS of $-6.23.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Novavax’s stock is considered to be oversold (<=20).
Yearly Top and Bottom Value
Novavax’s stock is valued at $4.99 at 16:32 EST, way under its 52-week high of $11.36 and way above its 52-week low of $3.53.
Volume
Today’s last reported volume for Novavax is 14453700 which is 57.06% above its average volume of 9202300.
Previous days news about Novavax
- Novavax (nvax) reports Q4 loss, lags revenue estimates. According to Zacks on Wednesday, 28 February, "While Novavax has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
- Novavax (nvax) Q4 earnings: taking a look at key metrics versus estimates. According to Zacks on Wednesday, 28 February, "For the quarter ended December 2023, Novavax (NVAX Quick QuoteNVAX – Free Report) reported revenue of $291.34 million, down 18.5% over the same period last year. ", "Here is how Novavax performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"
More news about Novavax.
8. LendingTree (TREE) – 11.41%
LendingTree, Inc., through its subsidiary, LT Intermediate Company, LLC, operates online consumer platform in the United States. It operates through three segments: Home, Consumer, and Insurance. The Home segment offers purchase mortgage, refinance mortgage, reverse mortgage, and home equity loans; lines of credit; and real estate brokerage services. The Consumer segment provides credit cards; personal, small business, student, and auto loans; deposit accounts; and other credit products, such as credit repair and debt settlement services. The Insurance segment includes information, tools, and access to insurance quote products, including home and automobile, through which consumers are matched with insurance lead aggregators to obtain insurance offers. In addition, the company offers QuoteWizard.com, a marketplace for insurance comparison; ValuePenguin, a personal finance website that offers consumers objective analysis on various financial topics from insurance to credit cards; and Stash, a consumer investing and banking platform that offers a suite of personal investment accounts, traditional and Roth IRAs, custodial investment accounts, and banking services, including checking accounts and debit cards with a Stock-Back rewards program. The company was formerly known as Tree.com, Inc. and changed its name to LendingTree, Inc. in January 2015. LendingTree, Inc. was incorporated in 1996 and is based in Charlotte, North Carolina.
NASDAQ ended the session with LendingTree rising 11.41% to $39.40 on Thursday, following the last session’s upward trend. NASDAQ rose 0.9% to $16,091.92, following the last session’s downward trend on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, LendingTree has a trailing twelve months EPS of $-9.46.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -94.15%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
LendingTree’s EBITDA is 57.74.
More news about LendingTree.
9. Catalyst Pharmaceuticals (CPRX) – 9.62%
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
NASDAQ ended the session with Catalyst Pharmaceuticals jumping 9.62% to $15.96 on Thursday while NASDAQ jumped 0.9% to $16,091.92.
Earnings Per Share
As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.55.
PE Ratio
Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 29.02. Meaning, the purchaser of the share is investing $29.02 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.06%.
Volatility
Catalyst Pharmaceuticals’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.07%, a negative 0.03%, and a positive 2.53%.
Catalyst Pharmaceuticals’s highest amplitude of average volatility was 1.07% (last week), 1.85% (last month), and 2.53% (last quarter).
Earnings Before Interest, Taxes, Depreciation, and Amortization
Catalyst Pharmaceuticals’s EBITDA is -37.42.
Yearly Top and Bottom Value
Catalyst Pharmaceuticals’s stock is valued at $15.96 at 16:32 EST, way under its 52-week high of $18.22 and way higher than its 52-week low of $11.09.
More news about Catalyst Pharmaceuticals.
10. AMD (AMD) – 8.02%
Advanced Micro Devices, Inc. operates as a semiconductor company worldwide. It operates through Data Center, Client, Gaming, and Embedded segments. The company offers x86 microprocessors and graphics processing units (GPUs) as an accelerated processing unit, chipsets, data center, and professional GPUs; and embedded processors, and semi-custom system-on-chip (SoC) products, microprocessor and SoC development services and technology, data processing unites, field programmable gate arrays (FPGA), and adaptive SoC products. It provides processors under the AMD Ryzen, AMD Ryzen PRO, Ryzen Threadripper, Ryzen Threadripper PRO, AMD Athlon, AMD Athlon PRO, and AMD PRO A-Series brand names; graphics under the AMD Radeon graphics and AMD Embedded Radeon graphics; and professional graphics under the AMD Radeon Pro graphics brand name. In addition, the company offers data center graphics under the Radeon Instinct and Radeon PRO V-series brands, as well as servers under the AMD Instinct accelerators brand; server microprocessors under the AMD EPYC brands; low power solutions under the AMD Athlon, AMD Geode, AMD Ryzen, AMD EPYC, AMD R-Series, and G-Series brands; FPGA products under the Virtex-6, Virtex-7, Virtex UltraScale+, Kintex-7, Kintex UltraScale, Kintex UltraScale+, Artix-7, Artix UltraScale+, Spartan-6, and Spartan-7 brands; adaptive SOCs under the Zynq-7000, Zynq UltraScale+ MPSoC, Zynq UltraScale+ RFSoCs, Versal HBM, Versal Premium, Versal Prime, Versal AI Core, Versal AI Edge, Vitis, and Vivado brands; and compute and network acceleration board products under the Alveo brand. It serves original equipment and design manufacturers, public cloud service providers, system integrators, independent distributors, and add-in-board manufacturers through its direct sales force, and sales representatives. Advanced Micro Devices, Inc. was incorporated in 1969 and is headquartered in Santa Clara, California.
NASDAQ ended the session with AMD jumping 8.02% to $190.70 on Thursday while NASDAQ jumped 0.9% to $16,091.92.
Earnings Per Share
As for profitability, AMD has a trailing twelve months EPS of $0.53.
PE Ratio
AMD has a trailing twelve months price to earnings ratio of 359.8. Meaning, the purchaser of the share is investing $359.8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.54%.
Volatility
AMD’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.73%, a positive 0.02%, and a positive 2.37%.
AMD’s highest amplitude of average volatility was 1.48% (last week), 2.53% (last month), and 2.37% (last quarter).
More news about AMD.
Losers Today
1. Castle Biosciences (CSTL) – -26.32%
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
NASDAQ ended the session with Castle Biosciences falling 26.32% to $17.97 on Thursday while NASDAQ rose 0.9% to $16,091.92.
Earnings Per Share
As for profitability, Castle Biosciences has a trailing twelve months EPS of $-2.84.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.94%.
More news about Castle Biosciences.
2. Canaan (CAN) – -15.67%
Canaan Inc. engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. It is also involved in the assembly and distribution of mining equipment and spare parts. The company has operations in the United States, Australia, Kazakhstan, Hong Kong, Canada, Mainland China, Thailand, Sweden, and internationally. Canaan Inc. was founded in 2013 and is based in Singapore.
NASDAQ ended the session with Canaan sliding 15.67% to $1.56 on Thursday, following the last session’s upward trend. NASDAQ jumped 0.9% to $16,091.92, following the last session’s downward trend on what was a somewhat up trend exchanging session today.
Earnings Per Share
As for profitability, Canaan has a trailing twelve months EPS of $-2.41.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -53.23%.
Yearly Top and Bottom Value
Canaan’s stock is valued at $1.56 at 16:32 EST, way below its 52-week high of $3.50 and way higher than its 52-week low of $1.13.
Volatility
Canaan’s last week, last month’s, and last quarter’s current intraday variation average was a negative 5.31%, a positive 0.13%, and a positive 8.17%.
Canaan’s highest amplitude of average volatility was 12.01% (last week), 8.81% (last month), and 8.17% (last quarter).
Moving Average
Canaan’s worth is way below its 50-day moving average of $1.95 and way below its 200-day moving average of $2.08.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Canaan’s stock is considered to be overbought (>=80).
More news about Canaan.
3. Marathon (MARA) – -15.65%
Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines digital assets with a focus on the blockchain ecosystem and the generation of digital assets in United States. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Fort Lauderdale, Florida.
NASDAQ ended the session with Marathon falling 15.65% to $26.17 on Thursday while NASDAQ jumped 0.9% to $16,091.92.
Earnings Per Share
As for profitability, Marathon has a trailing twelve months EPS of $-3.08.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -42.13%.
Volatility
Marathon’s last week, last month’s, and last quarter’s current intraday variation average was 7.71%, 2.62%, and 7.05%.
Marathon’s highest amplitude of average volatility was 9.30% (last week), 7.40% (last month), and 7.05% (last quarter).
Revenue Growth
Year-on-year quarterly revenue growth grew by 671.1%, now sitting on 259.16M for the twelve trailing months.
Moving Average
Marathon’s worth is way above its 50-day moving average of $21.56 and way higher than its 200-day moving average of $14.03.
Previous days news about Marathon
- Marathon digital stock forecast: MARA gyrates after reaching new two-year high. According to FXStreet on Tuesday, 27 February, "This means that the current block reward handed out to Bitcoin miners like Marathon Digital of 6.25 BTC will be halved to 3.125 BTC. "
More news about Marathon.
4. Viking Therapeutics (VKTX) – -15.27%
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
NASDAQ ended the session with Viking Therapeutics dropping 15.27% to $80.07 on Thursday, after five sequential sessions in a row of gains. NASDAQ rose 0.9% to $16,091.92, following the last session’s downward trend on what was a somewhat up trend exchanging session today.
Earnings Per Share
As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.91.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -34.79%.
Volatility
Viking Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was 3.89%, 2.43%, and 3.99%.
Viking Therapeutics’s highest amplitude of average volatility was 3.89% (last week), 3.55% (last month), and 3.99% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Viking Therapeutics’s stock is considered to be oversold (<=20).
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 12% and a negative 47.4%, respectively.
Yearly Top and Bottom Value
Viking Therapeutics’s stock is valued at $80.07 at 16:32 EST, way above its 52-week high of $38.68.
More news about Viking Therapeutics.
5. AMC (AMC) – -13.23%
AMC Entertainment Holdings, Inc., through its subsidiaries, engages in the theatrical exhibition business. The company owns, operates, or has interests in theatres in the United States and Europe. AMC Entertainment Holdings, Inc. was founded in 1920 and is headquartered in Leawood, Kansas.
NYSE ended the session with AMC falling 13.23% to $4.33 on Thursday, after four sequential sessions in a row of gains. NYSE jumped 0.23% to $17,613.45, following the last session’s downward trend on what was a somewhat up trend trading session today.
Compared to estimates, AMC entertainment (amc) Q4 earnings: A look at key metricsFor the quarter ended December 2023, AMC Entertainment (AMC Quick QuoteAMC – Free Report) reported revenue of $1.1 billion, up 11.5% over the same period last year. , Here is how AMC Entertainment performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Earnings Per Share
As for profitability, AMC has a trailing twelve months EPS of $-3.
Previous days news about AMC
- AMC entertainment (amc) reports Q4 loss, tops revenue estimates. According to Zacks on Wednesday, 28 February, "While AMC Entertainment has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?", "Ahead of this earnings release, the estimate revisions trend for AMC Entertainment: mixed. "
More news about AMC.
6. Riot Blockchain (RIOT) – -10.61%
Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. The company operates through Bitcoin Mining, Data Center Hosting, and Engineering segments. It also provides co-location services for institutional-scale bitcoin mining companies; critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners; operation of data centers; and maintenance/management of computing capacity. In addition, the company engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial, and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado.
NASDAQ ended the session with Riot Blockchain falling 10.61% to $13.99 on Thursday, after two sequential sessions in a row of losses. NASDAQ rose 0.9% to $16,091.92, following the last session’s downward trend on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, Riot Blockchain has a trailing twelve months EPS of $-0.28.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -3.25%.
Volatility
Riot Blockchain’s last week, last month’s, and last quarter’s current intraday variation average was 2.55%, 1.27%, and 5.34%.
Riot Blockchain’s highest amplitude of average volatility was 8.76% (last week), 6.07% (last month), and 5.34% (last quarter).
More news about Riot Blockchain.
7. FibroGen (FGEN) – -9.57%
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
NASDAQ ended the session with FibroGen falling 9.57% to $1.80 on Thursday while NASDAQ jumped 0.9% to $16,091.92.
Earnings Per Share
As for profitability, FibroGen has a trailing twelve months EPS of $-2.92.
Sales Growth
FibroGen’s sales growth is 13.2% for the ongoing quarter and 21.8% for the next.
Moving Average
FibroGen’s value is way higher than its 50-day moving average of $1.28 and way under its 200-day moving average of $3.79.
More news about FibroGen.
8. Cronos Group (CRON) – -9.29%
Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones brand in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
NASDAQ ended the session with Cronos Group sliding 9.29% to $2.05 on Thursday, following the last session’s downward trend. NASDAQ jumped 0.9% to $16,091.92, following the last session’s downward trend on what was a somewhat up trend trading session today.
Earnings Per Share
As for profitability, Cronos Group has a trailing twelve months EPS of $-0.31.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -9.97%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 95.2% and 100%, respectively.
More news about Cronos Group.
9. Xcel Energy (XEL) – -8.51%
Xcel Energy Inc., through its subsidiaries, engages in the generation, purchasing, transmission, distribution, and sale of electricity. It operates through Regulated Electric Utility, Regulated Natural Gas Utility, and All Other segments. The company generates electricity through wind, nuclear, hydroelectric, biomass, and solar energy sources, as well as coal, natural gas, oil, wood, and refuse-derived fuels. It also purchases, transports, distributes, and sells natural gas to retail customers, as well as transports customer-owned natural gas. In addition, the company develops and leases natural gas pipelines, and storage and compression facilities; and invests in rental housing projects and nonregulated assets, as well as procures equipment for the construction of renewable generation facilities. It serves residential, commercial, and industrial customers in the portions of Colorado, Michigan, Minnesota, New Mexico, North Dakota, South Dakota, Texas, and Wisconsin. The company was incorporated in 1909 and is headquartered in Minneapolis, Minnesota.
NASDAQ ended the session with Xcel Energy dropping 8.51% to $52.76 on Thursday, following the last session’s downward trend. NASDAQ rose 0.9% to $16,091.92, following the last session’s downward trend on what was a somewhat up trend exchanging session today.
Earnings Per Share
As for profitability, Xcel Energy has a trailing twelve months EPS of $3.21.
PE Ratio
Xcel Energy has a trailing twelve months price to earnings ratio of 16.44. Meaning, the purchaser of the share is investing $16.44 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.33%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 15.1%, now sitting on 14.21B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Xcel Energy’s EBITDA is 4.25.
Volatility
Xcel Energy’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.90%, a negative 0.09%, and a positive 0.94%.
Xcel Energy’s highest amplitude of average volatility was 1.30% (last week), 0.93% (last month), and 0.94% (last quarter).
More news about Xcel Energy.
10. Ambev (ABEV) – -6.32%
Ambev S.A., through its subsidiaries, engages in the production, distribution, and sale of beer, draft beer, carbonated soft drinks, other non-alcoholic beverages, malt, and food products. It offers beer primarily under the Skol, Brahma, Antarctica, Brahva, Budweiser, Bud Light, Beck, Leffe and Hoegaarden, Bucanero, Cristal, Mayabe, Presidente, Presidente Light, Brahma Light, Bohemia, The One, Corona, Modelo Especial, Stella Artois, Quilmes Clásica, Paceña, Taquiña, Huari, Becker, Cusqueña, Michelob Ultra, Busch, Pilsen, Ouro Fino, Banks, Deputy, Patricia, Labatt Blue, Alexander Keith's, and Kokanee brands. The company also provides carbonated soft drinks, bottled water, isotonic beverages, energy drinks, coconut water, powdered and natural juices, and ready-to-drink teas under the Guaraná Antarctica, Gatorade, H2OH!, Lipton Iced Tea, Fusion, Do Bem, Pepsi-Cola, Canada Dry, Squirt, Red Rock, Red Bull, Seven Up, Nutrl, Bud Light Seltzer, Palm Bay, and Mike's brands. It offers its products through a network of third-party distributors and a direct distribution system. The company was founded in 1885 and is headquartered in São Paulo, Brazil. Ambev S.A. operates as a subsidiary of Interbrew International B.V.
NYSE ended the session with Ambev sliding 6.32% to $2.52 on Thursday while NYSE jumped 0.23% to $17,613.45.
Earnings Per Share
As for profitability, Ambev has a trailing twelve months EPS of $0.19.
PE Ratio
Ambev has a trailing twelve months price to earnings ratio of 13.26. Meaning, the purchaser of the share is investing $13.26 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.95%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Dec 22, 2023, the estimated forward annual dividend rate is 0.15 and the estimated forward annual dividend yield is 5.9%.
Sales Growth
Ambev’s sales growth is 3.1% for the present quarter and 1.7% for the next.
Revenue Growth
Year-on-year quarterly revenue growth declined by 1.3%, now sitting on 82.44B for the twelve trailing months.
More news about Ambev.
Stay up to date with our winners and losers daily report
